Dr. Reddy’s Laboratories, an Indian drugmaker, has secured regional rights to two biosimilars developed by Bio-Thera, a Chinese biotech company. The agreement grants Dr. Reddy’s the right to develop, manufacture, and market the biosimilars, which are replicas of Amgen’s blockbuster drugs, in Asia, excluding China.
The two biosimilars, CT-P6 ( biosimilar to Avastin/Lucentis) and CT-P7 (biosimilar to Herceptin), are being developed by Bio-Thera through its partnership with Amgen. The agreement is expected to benefit patients by making these high-cost medications more accessible and affordable in Asia.
Dr. Reddy’s, with its presence in over 25 countries, will leverage its extensive network, expertise, and manufacturing capabilities to commercialize the biosimilars in the region. Bio-Thera will focus on the Chinese market, where it has a strong presence.
The deal marks a significant milestone for Dr. Reddy’s, which has been expanding its presence in the Asian market. The company has already made significant inroads in the region, with a diverse portfolio of products and a strong distribution network.
The agreement with Bio-Thera is expected to further strengthen Dr. Reddy’s position in the Asian market, particularly in countries such as India, Indonesia, Malaysia, the Philippines, and Thailand, where there is a growing demand for high-quality, affordable healthcare solutions.
In addition to the Asia region, Dr. Reddy’s has also made strategic investments in the Latin American and Eastern European markets, demonstrating its commitment to expanding its global footprint.
The partnership with Bio-Thera is a testament to Dr. Reddy’s commitment to embracing innovative technologies and partnerships to drive growth. The deal is expected to create new opportunities for the company, improve patient access to high-quality medications, and contribute to Dr. Reddy’s growth in the Asian market.
Overall, the agreement between Dr. Reddy’s and Bio-Thera is a significant development in the biopharmaceutical industry, highlighting the growing trend of partnerships and collaborations to drive growth, improve patient access, and create new opportunities in the region.